These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 19430379

  • 1. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease.
    Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T.
    Pediatr Res; 2009 Jun; 65(6):696-701. PubMed ID: 19430379
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
    Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
    [Abstract] [Full Text] [Related]

  • 4. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X, Saito K, Uese K, Miyawaki T, Viemann D, Roth J, Foell D.
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [Abstract] [Full Text] [Related]

  • 5. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
    Stenbøg EV, Windelborg B, Hørlyck A, Herlin T.
    Scand J Rheumatol; 2006 Dec; 35(4):318-21. PubMed ID: 16882598
    [Abstract] [Full Text] [Related]

  • 6. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 7. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
    Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Honda T, Onouchi Y, Terai M, Hata A.
    Cytokine; 2012 Dec 17; 60(3):681-5. PubMed ID: 22944461
    [Abstract] [Full Text] [Related]

  • 8. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
    J Pediatr; 2011 Apr 17; 158(4):644-649.e1. PubMed ID: 21129756
    [Abstract] [Full Text] [Related]

  • 9. Infliximab treatment for refractory Kawasaki syndrome.
    Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME.
    J Pediatr; 2005 May 17; 146(5):662-7. PubMed ID: 15870671
    [Abstract] [Full Text] [Related]

  • 10. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
    Ogihara Y, Ogata S, Nomoto K, Ebato T, Sato K, Kokubo K, Kobayashi H, Ishii M.
    Pediatr Res; 2014 Sep 17; 76(3):287-93. PubMed ID: 24964229
    [Abstract] [Full Text] [Related]

  • 11. [Cytokines in Kawasaki disease].
    Abe J.
    Nihon Rinsho; 2014 Sep 17; 72(9):1548-53. PubMed ID: 25518401
    [Abstract] [Full Text] [Related]

  • 12. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
    J Rheumatol; 2004 Apr 17; 31(4):808-10. PubMed ID: 15088313
    [Abstract] [Full Text] [Related]

  • 13. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 17; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 14. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
    Int J Rheum Dis; 2013 Apr 17; 16(2):168-72. PubMed ID: 23773640
    [Abstract] [Full Text] [Related]

  • 15. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS, Durán DG, Peracaula CS, Iznardi CR, Tardío JO.
    An Pediatr (Barc); 2010 Nov 17; 73(5):268-71. PubMed ID: 20678974
    [Abstract] [Full Text] [Related]

  • 16. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
    Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.
    Clin Exp Immunol; 2013 Dec 17; 174(3):337-44. PubMed ID: 23901839
    [Abstract] [Full Text] [Related]

  • 17. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
    Sakurai Y, Takatsuka H, Onaka M, Takada M, Nishino M.
    Int Arch Allergy Immunol; 2014 Dec 17; 165(2):111-8. PubMed ID: 25401215
    [Abstract] [Full Text] [Related]

  • 18. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.
    J Pediatr; 2008 Dec 17; 153(6):833-8. PubMed ID: 18672254
    [Abstract] [Full Text] [Related]

  • 19. [Regulation of proinflammatory cytokine cascade in Kawasaki disease].
    Furukawa S, Matsubara T, Ichiyama T.
    Nihon Rinsho; 2008 Feb 17; 66(2):258-64. PubMed ID: 18260323
    [Abstract] [Full Text] [Related]

  • 20. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease.
    Hirono K, Foell D, Xing Y, Miyagawa-Tomita S, Ye F, Ahlmann M, Vogl T, Futatani T, Rui C, Yu X, Watanabe K, Wanatabe S, Tsubata S, Uese K, Hashimoto I, Ichida F, Nakazawa M, Roth J, Miyawaki T.
    J Am Coll Cardiol; 2006 Sep 19; 48(6):1257-64. PubMed ID: 16979015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.